– Vorasidenib Demonstrated Prolonged Disease Control and Encouraging Preliminary Activity with Median Progression-free Survival of 31.4 Months –– Vorasidenib Demonstrated […]
MALVERN, Penn., May 29, 2020 (GLOBE NEWSWIRE) — Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing […]
JACKSONVILLE, Fla., May 29, 2020 (GLOBE NEWSWIRE) — Regency Centers Corporation (“Regency” or the “Company”) (NASDAQ:REG) today announced that Lisa […]